All News

cancer.cross_.jpg

No Cancer Recurrence with Biologic DMARDs in RA

Jack Cush, MD

A prospective Danish rheumatoid arthritis (RA) registry study look at the risk of recurrence when a biological disease-modifying antirheumatic drugs (bDMARDs) was ued in patients with a a prior solid cancer (in remission) and found no increased cancer

Read Article
syringe, pill, DMARD, Treatment, therapy

Tocilizumab vs. Methotrexate in Rheumatoid Arthritis

Jack Cush, MD

A large randomized rheumatoid arthritis (RA) clinical trial compared subcutaneous tocilizumab (TCZ) vs oral methotrexate (MTX) vs. the combination of subcutaneous TCZ and MTX, and showed that TCZ was superior to MTX, either given as TCZ monotherapy or in combination with MTX. 

Read Article
key solution goal plan problem solve

Moving Targets in Lupus and Lupus Trials

Joan T. Merrill, MD

Clinical trial data quality is a moving target. Lupus is also a moving target. Can we address the moving target of lupus pathology with the moving targets of quality clinical trials and scientific treatment selection?

Read Article
Biologic.choice.MD_.jpeg (keep)

Biologics in Pregnancy Patients With Autoimmune Disease

Jack Cush, MD

A large cohort, claims data study shows that among pregnant women receiving biologic therapies for autoimmune conditions, 72% continued their biologics pregnancy, more so among inflammatory bowel disease (IBD) patients than those with rheumatoid arthritis (RA), psoriasis (PsO) or psoriatic arthri

Read Article
pregnancy,doctor,consult

SLE, Antiphospholipid Antibodies, and the Placenta

Catherine Sims, MD

It is well established that women with SLE are at increased risk for adverse pregnancy outcomes, including preeclampsia, preterm birth, and pregnancy loss. However, the pathophysiologic mechanisms driving these complications are not yet fully understood. In this article, we explore several proposed pathways where the immune system and placenta interface, summarized in Figure 1, that may enhance our understanding of these risks.

Read Article
#Proteinuria that persists in #LN #lupus #nephritis even w mild proteinuria 👇 Worse outcomes Just like all CKD Take home Aim for None or minimal in #SLE <150 protein #voclosporin >> PBO (SoC) 1/2 Voclosporin had deep response at least once > PBO #LUPUS2025 @RheumNow https://t.co/CBUzyBatBh

Links:

Janet Pope Janetbirdope ( View Tweet)
Moving Targets in Lupus and Lupus Trials In the 1990s, lupus treatment development became a major focus, but progress was slow. Belimumab was eventually approved by recognizing that trials could only show small differences from placebo, requiring 867 patients globally to https://t.co/xrj8r1iNxr
Dr. John Cush RheumNow ( View Tweet)
If vagus nerve stimulation improves RA; then what if vagotomy? Danish study of vagotomy (1977-1995). 6070 vagotomy matched w/ 60,699 comparators. Truncal vagotomy was assoc w/ signif incr RA incidence (OR 2.62), but not superselective vagotomy (OR 1.05). NO diff in incident OA https://t.co/Rs1EyrQd57
Dr. John Cush RheumNow ( View Tweet)
Periprosthetic femoral Fx (PPFF): metanalysis of 36 studies found PPFF risk factors: Uncemented stems (OR 3.36), major teaching hosp (2.0), female (1.6), obesity (1.4), Hi comorbidity(1.4), RA (1.89), (1.67), revised THR (2.6). OA = protective (0.51) https://t.co/y2BpH8LUb6 https://t.co/hX2lcjI4Kg

Links:

Dr. John Cush RheumNow ( View Tweet)
Assessing and Treating CV Risk Increases in Systemic Lupus For nearly 50 years, the heightened CVD risk in SLE patients has been acknowledged since Urowitz et al.'s 1976 study on lupus mortality. Research consistently shows SLE patients have a 2-10 times higher CVD risk than https://t.co/P1AdxHkiQi
Dr. John Cush RheumNow ( View Tweet)
Emulation trials in SLE: Real or Fake? Recently a landmark paper was published in A&R studying the results of an emulation trial. My colleagues and I were able to write an editorial on this paper and describe emulation trials. https://t.co/0ulYG5xz0J https://t.co/y2jo2SSH83

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE Perspectives: Past, Present, Future https://t.co/ggYmVvEtZx https://t.co/VriDjAEcl5

Links:

Dr. John Cush RheumNow ( View Tweet)
Risk Factors for Knee Osteoarthritis New research from the University of Sydney reveals that obesity, having a knee injury and occupational risks such as shift work and lifting heavy loads are primary causes of knee osteoarthritis. https://t.co/Kc686Zc8Xa https://t.co/ANyiE2pIxo

Links:

Dr. John Cush RheumNow ( View Tweet)
New Steroid Rules in Lupus? Let’s Talk. Dr. Michelle Petri breaks down the latest strategies to minimize steroid exposure while managing disease activity in lupus patients. 💡 Smarter steroid use = better outcomes. 👉 Watch now on RheumNow: https://t.co/vbjrXAlixz #Lupus https://t.co/TN5EkZhbef

Links:

Dr. John Cush RheumNow ( View Tweet)
Clinical Impacts of the Pre Lupus State on Pregnancy Outcomes Dr. Catherine Sims talks with Dr. Jessica English at the RheumaPreg 2025 meeting in Vienna, Austria. https://t.co/T8ZYQtDNmZ https://t.co/PmVRFVlABd

Links:

Dr. John Cush RheumNow ( View Tweet)
3-year, RCT of Mediteranean diet vs usual care in 924 older adults w/ metabolic syndrome & BMI > 27. Med. diet shows signif wt loss (3.4% vs 0.4%), w/ improved BMD (by DEXA) at year 3, especially in women. https://t.co/mllx6l1QnM https://t.co/CulO1Sschf

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study 112 biopsy-proven Lupus nephritis pts (65% class IV; F/U 8.3 yrs). (64.3%), alone or in combination. Renal damage incr betw 5 & 10 yrs F/U. 13.4% progressed to renal function impairment, and 11.6% to ESRD. Early Dx & Rx of LN, esp w/ highproteinuria, https://t.co/N1BL9Bri3M
Dr. John Cush RheumNow ( View Tweet)
Lessons Learned from a Lupus Registry: Two sides of one coin? It's Dr. Janet Pope reporting at RheumNow on our special lupus edition. I'd like to talk about lessons learned from a Canadian lupus registry. Is it two sides of one coin? https://t.co/IxMZhA1uht https://t.co/PJixCj8d6g

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Refractory Renal SLE How to manage class III/IV lupus glomerulonephritis when you run out of options Features Dr. Jack Cush. https://t.co/8CQm8GZ213 https://t.co/lJKvcpIq60

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study 112 biopsy-proven Lupus nephritis pts (65% class IV; F/U 8.3 yrs). (64.3%), alone or in combination. Renal damage incr betw 5 & 10 yrs F/U. 13.4% progressed to renal function impairment, and 11.6% to ESRD. Early Dx & Rx of LN, esp w/ highproteinuria, https://t.co/yHzN1Hczb4
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×